ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Carrington And Brookwood Pharmaceuticals Expand GelSite(R) Drug Delivery Technology Development
Carrington
Laboratories, Inc. (Nasdaq: CARN) announced today that its subsidiary,
DelSite Biotechnologies, Inc., formed a joint development initiative with
Brookwood Pharmaceuticals, Inc. The goal of this effort is to carry out an
expanded evaluation of GelSite(R), a DelSite patented drug-delivery
technology, as a matrix for injectable applications and for selected
classes of drugs.
GelSite(R) is a naturally derived, biocompatible, resorbable biopolymer
that can be used to deliver biopharmaceuticals. This technology has the
potential to protect and deliver peptides and proteins effectively while
reducing the frequency of drug administration. Fewer injections will
improve patient compliance, safety and efficacy. Injectable,
controlled-release applications for peptides and proteins are in the
multibillion-dollar drug delivery market.
"The team at DelSite has been making great strides with the GelSite(R)
technology, particularly in the vaccine area. We are excited to be
collaborating with them -- combining our teams of polymer and drug delivery
experts -- to broadly evaluate parenteral applications," said Dr. Arthur J.
Tipton, President and CEO.
Under this new expanded joint development initiative, the evaluation of
GelSite(R) technology will be managed by a team of experts from Brookwood
Pharmaceuticals and DelSite. "Brookwood Pharmaceuticals is internationally
recognized for its pioneering contributions in the drug delivery field,
particularly for the development of long-acting parenteral formulations,
including injectable microparticles and injectable solid implants," said
Dr. Carlton E. Turner, president and CEO of Carrington.
Dr. Thomas R. Tice, Executive Vice President and CSO, added, "I have
been interested in this technology for some time. We have previously worked
in specified areas with DelSite, but now with this broader collaboration, I
think our teams will likely develop a range of interesting applications."
About Brookwood Pharmaceuticals
Brookwood Pharmaceuticals, Inc. is a product-focused, drug-delivery
company based in Birmingham, Alabama. Brookwood's drug-delivery
technologies include long-acting parenteral formulations -- injectable
microparticles and injectable solid implants -- for the delivery of
peptides, small molecules, proteins, nucleic acids, and other biological
macromolecules. Brookwood's capabilities include development of
physician-administered and self- administered formulations that are
effective for days and months following a single administration.
Client-partnered, development programs begin with evaluation studies, and
then proceed to pre-clinical development, clinical trial manufacturing and
commercial manufacturing. Contract manufacturing of clinical supplies and
commercial product includes production of drug-delivery formulations such
as microparticles, nanoparticles, liposomes, implants, and microparticles
of hydrophobic salts. Brookwood's subsidiary, Lakeshore Biomaterials,
manufactures biodegradable polymers for drug-delivery products and medical
devices.
For further information, see http://www.brookwoodpharma.com.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based,
biopharmaceutical and consumer products company currently utilizing
naturally- occurring complex carbohydrates to manufacture and market
products for mucositis, radiation dermatitis, wound and oral care, as well
as to manufacture and market the nutraceutical raw material Manapol(R) and
cosmetic raw material Hydrapol(TM). Carrington also manufactures and
markets consumer products and manufactures quality products for other
companies. Manufacturing operations comply with cGMP standards.
Carrington's DelSite Biotechnologies subsidiary is developing its
proprietary GelSite(R) technology designed to provide controlled release of
peptide and protein-based drugs. Carrington's technology is protected by
more than 130 patents in 26 countries. Select products carry the CE mark,
recognized by more than 20 countries around the world.
For more information, visit http://www.carringtonlabs.com.
Certain statements in this release concerning Carrington may be
forward- looking. Actual events will be dependent upon a number of factors
and risks including, but not limited to: subsequent changes in plans by the
Company's management; delays or problems in formulation, manufacturing,
distribution, production and/or launch of new finished products; changes in
the regulatory process; changes in market trends; and a number of other
factors and risks described from time to time in the Company's filings with
the Securities & Exchange Commission, including the Form 10-Q, filed May 5,
2006.
Carrington Laboratories, Inc.
http://www.carringtonlabs.com
View drug information on Carrington patch.
Carrington ªi Brookwood Pharmaceuticals Expand GelSite (R) Drug Delivery dezvoltare tehnologicã - Carrington And Brookwood Pharmaceuticals Expand GelSite(R) Drug Delivery Technology Development - articole medicale engleza - startsanatate